New Delhi: The R21Matrix-M vaccine for malaria developed at the University of Oxford will be produced in India. The university said that under the agreement with the Serum Institute of India (CII), the vaccines produced in India will be used first in the African country of Ghana.
Vaccine scientists say that this will reduce about 5 lakh deaths in the world every year. The vaccine has been tested in the UK, Thailand, Burkina Faso, Kenya, Mali, and Tanzania. Their results will be released at the end of the year. SII CEO Adar Poonawala said 200 million vaccines will be produced in a year.
Professor Adrian Hill, involved in vaccine development, said it was the result of 30 years of research on malaria vaccines at Oxford. He informed me that a saponin-based adjuvant from Novavax has been used in Matrix-M. It enhances the response of the immune system, making its effect more potent and lasting.
Foot overbridge collapses in Udhampur
'No free electricity in Delhi from today', Kejriwal government reversed after its announcement
'Raped for 5 years after friendship on Instagram', girl tells police